Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥82,293,000 | ¥81,964,000 | ¥82,730,000 | ¥86,813,000 |
| % Growth | 0.4% | -0.9% | -4.7% | – |
| Cost of Goods Sold | ¥37,463,000 | ¥36,111,000 | ¥37,473,000 | ¥36,324,000 |
| Gross Profit | ¥44,830,000 | ¥45,853,000 | ¥45,257,000 | ¥50,489,000 |
| % Margin | 54.5% | 55.9% | 54.7% | 58.2% |
| R&D Expenses | ¥3,355,000 | ¥3,386,000 | ¥3,239,000 | ¥3,530,000 |
| G&A Expenses | ¥0 | ¥0 | -¥38,583,000 | ¥0 |
| SG&A Expenses | ¥33,973,000 | ¥34,226,000 | ¥35,477,000 | ¥31,946,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥57,506,000 | ¥0 |
| Other Operating Expenses | ¥0 | -¥3,458,000 | ¥0 | ¥537,000 |
| Operating Expenses | ¥37,328,000 | ¥34,154,000 | ¥38,716,000 | ¥36,013,000 |
| Operating Income | ¥7,502,000 | ¥11,699,000 | ¥6,541,000 | ¥14,476,000 |
| % Margin | 9.1% | 14.3% | 7.9% | 16.7% |
| Other Income/Exp. Net | ¥970,000 | ¥3,374,000 | ¥995,000 | ¥1,743,000 |
| Pre-Tax Income | ¥8,472,000 | ¥15,073,000 | ¥7,536,000 | ¥16,219,000 |
| Tax Expense | ¥2,753,000 | ¥3,021,000 | ¥1,196,000 | ¥4,417,000 |
| Net Income | ¥5,884,000 | ¥11,769,000 | ¥6,200,000 | ¥11,885,000 |
| % Margin | 7.2% | 14.4% | 7.5% | 13.7% |
| EPS | 26.04 | 52.08 | 27.34 | 51.95 |
| % Growth | -50% | 90.5% | -47.4% | – |
| EPS Diluted | 25.01 | 51.39 | 27.04 | 51.95 |
| Weighted Avg Shares Out | 225,964 | 229,013 | 229,210 | 228,763 |
| Weighted Avg Shares Out Dil | 235,210 | 229,013 | 229,210 | 228,763 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥251,000 | ¥237,000 | ¥241,000 | ¥274,000 |
| Interest Expense | ¥286,000 | ¥316,000 | ¥385,000 | ¥436,000 |
| Depreciation & Amortization | ¥3,992,000 | ¥3,285,750 | ¥4,645,000 | ¥2,171,750 |
| EBITDA | ¥12,748,000 | ¥14,912,750 | ¥12,558,000 | ¥16,524,750 |
| % Margin | 15.5% | 18.2% | 15.2% | 19% |